Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is neutral on EV/EBITDA.
Target Price
The average target price of PHAT is 23 and suggests 122% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell